Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Remus Pharmaceuticals Limited is an India-based company that is engaged in the marketing and distribution of finished formulations of pharmaceutical drugs. It also deals in active pharmaceutical ingredients (API). The Company also provides technical consulting services to various distributors for the preparation of reports on the dossiers of the products. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, and tablet. The Company’s business verticals include the sale of finished formulations, the sale of APIs, and technical consulting. Its product portfolio comprises a range of therapeutic drugs, namely ACE inhibitors, analgesics, anti-erectile dysfunction, anti-fibrinolytics, anti-histamines, beta blockers, carcinoid tumors, chronic obstructive pulmonary disease, and contrast reagents, among others.
Customise key metrics, see detailed forecasts, download stock data and more
In last 3 months, mutual fund holding of the company has almost stayed constant
Interim 2 • Div/Share: ₹ 4
Interim • Div/Share: ₹ 2
Final • Div/Share: ₹ 2
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant